https://www.selleckchem.com/pr....oducts/vorapaxar.htm
38, 95% CI 0.15-0.98, p=0.047) and OS (HR 0.37, 95% CI 0.13-0.99, p=0.047). In subgroup analysis, the CR after CCRT followed by ACT group showed significantly higher locoregional recurrence-free survival (p=0.02), OS (p=0.003), distant-metastasis free survival (p=0.07), and PFS (p=0.01) than the other three groups. Tumor regression 1month after CCRT, and administration of ACT identified as an independent prognosticator for PFS and OS in this study. Even patients who show early tumor regression after CCRT may benefit from ACT. Further